A detailed history of D. E. Shaw & Co., Inc. transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 532,404 shares of AGIO stock, worth $17.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
532,404
Holding current value
$17.1 Million
% of portfolio
0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$41.19 - $49.72 $6.01 Million - $7.25 Million
-145,830 Reduced 21.5%
532,404 $23.7 Million
Q2 2024

Aug 14, 2024

BUY
$27.55 - $48.83 $8.71 Million - $15.4 Million
316,100 Added 87.29%
678,234 $29.2 Million
Q1 2024

May 15, 2024

BUY
$21.32 - $34.81 $3.11 Million - $5.07 Million
145,650 Added 67.28%
362,134 $10.6 Million
Q4 2023

Feb 14, 2024

BUY
$19.97 - $24.53 $1.16 Million - $1.43 Million
58,204 Added 36.77%
216,484 $4.82 Million
Q3 2023

Nov 14, 2023

BUY
$24.36 - $28.18 $1.52 Million - $1.76 Million
62,420 Added 65.12%
158,280 $3.92 Million
Q2 2023

Aug 14, 2023

SELL
$21.38 - $29.19 $134,394 - $183,488
-6,286 Reduced 6.15%
95,860 $2.71 Million
Q1 2023

May 15, 2023

SELL
$21.74 - $30.93 $1.38 Million - $1.97 Million
-63,652 Reduced 38.39%
102,146 $2.35 Million
Q4 2022

Feb 14, 2023

SELL
$24.81 - $31.52 $3.11 Million - $3.96 Million
-125,493 Reduced 43.08%
165,798 $4.66 Million
Q3 2022

Nov 14, 2022

BUY
$19.51 - $34.14 $290,152 - $507,730
14,872 Added 5.38%
291,291 $8.24 Million
Q2 2022

Aug 15, 2022

BUY
$17.06 - $31.42 $3.85 Million - $7.1 Million
225,876 Added 446.9%
276,419 $6.13 Million
Q1 2022

May 16, 2022

SELL
$26.68 - $34.81 $1.69 Million - $2.2 Million
-63,323 Reduced 55.61%
50,543 $1.47 Million
Q4 2021

Feb 14, 2022

SELL
$29.58 - $49.78 $795,347 - $1.34 Million
-26,888 Reduced 19.1%
113,866 $3.74 Million
Q3 2021

Nov 15, 2021

BUY
$41.92 - $58.18 $5 Million - $6.94 Million
119,366 Added 558.1%
140,754 $6.5 Million
Q2 2021

Aug 16, 2021

SELL
$52.06 - $61.27 $3.38 Million - $3.98 Million
-64,970 Reduced 75.23%
21,388 $1.18 Million
Q1 2021

May 17, 2021

SELL
$44.23 - $57.5 $4.41 Million - $5.73 Million
-99,672 Reduced 53.58%
86,358 $4.46 Million
Q4 2020

Feb 16, 2021

SELL
$33.21 - $46.54 $4.97 Million - $6.96 Million
-149,640 Reduced 44.58%
186,030 $8.06 Million
Q3 2020

Nov 16, 2020

BUY
$33.87 - $55.93 $2.56 Million - $4.23 Million
75,626 Added 29.08%
335,670 $11.7 Million
Q2 2020

Aug 14, 2020

BUY
$34.45 - $53.48 $1.13 Million - $1.75 Million
32,741 Added 14.4%
260,044 $13.9 Million
Q1 2020

May 15, 2020

SELL
$31.52 - $53.81 $862,733 - $1.47 Million
-27,371 Reduced 10.75%
227,303 $8.07 Million
Q4 2019

Feb 14, 2020

BUY
$30.08 - $50.59 $7.15 Million - $12 Million
237,759 Added 1405.61%
254,674 $12.2 Million
Q3 2019

Nov 14, 2019

SELL
$32.4 - $49.58 $1.63 Million - $2.49 Million
-50,197 Reduced 74.8%
16,915 $548,000
Q2 2019

Aug 14, 2019

SELL
$46.17 - $68.1 $5.92 Million - $8.73 Million
-128,201 Reduced 65.64%
67,112 $3.35 Million
Q1 2019

May 15, 2019

SELL
$45.92 - $67.67 $5.09 Million - $7.5 Million
-110,782 Reduced 36.19%
195,313 $13.2 Million
Q4 2018

Feb 14, 2019

BUY
$42.73 - $76.53 $4.46 Million - $7.99 Million
104,383 Added 51.75%
306,095 $14.1 Million
Q3 2018

Nov 14, 2018

BUY
$71.67 - $91.95 $57,120 - $73,284
797 Added 0.4%
201,712 $15.6 Million
Q2 2018

Aug 14, 2018

BUY
$73.22 - $99.55 $190,372 - $258,830
2,600 Added 1.31%
200,915 $16.9 Million
Q1 2018

May 15, 2018

BUY
$59.83 - $86.53 $9.59 Million - $13.9 Million
160,327 Added 422.05%
198,315 $16.2 Million
Q4 2017

Feb 14, 2018

BUY
$52.12 - $72.33 $1.98 Million - $2.75 Million
37,988
37,988 $2.17 Million

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $1.76B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.